Exforge antitrust settlement caps Novartis’ year of legal disputes
Pharmaceutical Technology
JANUARY 6, 2023
At the centre of the case was Gilenya’s ‘405 patent, which details methods for treating relapsing multiple sclerosis with a specific dosage of the drug. The court filing showed that the patent details a daily administration of 0.5mg Gilenya. Please check your email to download the Report.
Let's personalize your content